Biosimilars: Regulatory, Quality, and Manufacturing Excellence

At ADRES, we specialize in guiding companies through the intricate journey of biosimilar development. 

Our expertise in Regulatory Affairs (RA), Quality Assurance (QA), and Chemistry, Manufacturing, and Controls (CMC) positions us uniquely to support biosimilar projects.

Regulatory Affairs: 

Navigating the complex regulatory landscape is crucial for biosimilar development success. 
We provide strategic regulatory planning, dossier preparation, and liaise with regulatory bodies, ensuring compliance with the stringent standards for biosimilars.

Quality Assurance: 

Biosimilars development require meticulous QA processes. Our team ensures the highest quality standards are met, from development to market. 
We implement robust quality systems, conduct audits, and ensure continuous quality improvement, aligning with global regulatory requirements.

Chemistry, Manufacturing, and Controls: 

The manufacturing of biosimilars demands precision. We assist in developing and optimizing manufacturing processes, ensuring scalability and cost-effectiveness. 
Our CMC expertise covers process development, validation, and technology transfer, ensuring consistent and high-quality biosimilar production.

For biosimilar developers, partnering with ADRES International means gaining a trusted ally, committed to excellence and success in bringing your biosimilar products to market.

Connect us, Let’s innovate together for a healthier future.


Go back to the Blog

Unlocking Biotech Valuation: Orphan Drug Impact & Regulatory Compliance

By: Lital Israeli Yagev

Nurexone has recently been granted Orphan Drug Designation by the FDA for their groundbreaking treatment in Spinal Cord Injury (SCI) and is now seeking the same designation in the European Union.

💡 Why does this matter? 

Orphan Drug Designation is more than just a regulatory compliance milestone. It’s a gateway to valuable incentives including tax credits, waived fees, and most importantly, exclusive marketing rights for a significant period upon approval. This not only accelerates the path to market but also enhances the commercial potential of innovative treatments.

📈 Reflecting the market’s confidence, 

Nurexone’s stock surged an impressive 78%, underscoring the positive impact of Orphan Drug Designation on biotech firms. This trend aligns with recent studies, showing that such designations can lead to substantial increases in company valuations, driven by the promising outlook of their pipeline.

At ADRES, we understand the intricacies and the immense value of Orphan Drug Designations.

Our expert regulatory consulting team has a proven track record in navigating this complex landscape, offering strategic guidance and comprehensive support to secure these designations in the US and EU. Whether it’s crafting compelling applications or articulating a strong scientific rationale, we’re here to turn challenges into opportunities.

Looking to explore how Orphan Drug Designation can transform your biotech venture? Connect us, Let’s innovate together for a healthier future.

Go back to the Blog
Skip to content